Journal
DERMATOLOGY
Volume 205, Issue 2, Pages 172-173Publisher
KARGER
DOI: 10.1159/000063900
Keywords
adverse drug reaction; STI571; leukemia; Gleevec
Categories
Ask authors/readers for more resources
A tyrosine kinase inhibitor (STI571, Gleevec) has recently been applied in the treatment of chronic myeloid leukemia. We present the first reported case of pityriasis rosea occurring as a reaction to Gleevec in a woman with blast crisis of this disorder. It is suggested that although coincidental, this exanthem may be due to this agent. Copyright (C) 2002 S. Karger AG, Basel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available